Industry Briefs: Apr. 23, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 23, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

3M Drug Delivery Systems has expanded its pressurized metered dose inhaler fill line at its facility in Northridge, California. Read More

Baxter International will invest $1 billion over the next five years for a new manufacturing facility in Georgia for plasma-derived therapies. Read More

Eisai has amended its license agreement with Teikoku Pharma USA for the Aricept transdermal patch system. Read More

Kemwell Biopharma has expanded its pharmaceutical development laboratories, including a 7500-ft2 cGMP pilot facility, in Bangalore, India, to support pharmaceutical projects from preformulation to finished products.

Merck Millipore, the life-science division of Merck KGaA, has announced the schedule for the Merck Millipore Live Lab Tour 2012 that will visit nine science parks and institutions in Europe during May–June 2012. Click here for the schedule and more details.

Mylan is expanding its operations in Dublin and Galway, Ireland. Read More

Patheon has formed Patheon Certified Consultants, a new consulting services comprised of industry professionals to assist emerging biotechnology and pharmaceutical companies. Read More

West Pharmaceutical Services has dedicated new cleanroom manufacturing capabilities at its Scottsdale, Arizona, pharmaceutical delivery systems engineering center. West will manufacture its Daikyo Crystal Zenith 1-mL long prefillable syringe system at the Scottsdale facility.

People News

AMRI has appointed Christopher Conway and Louis Garguilo as vice-president in its business-development units. Read More

Novasep has appointed Jean-Claude Romain as corporate quality director and Alain Lamproye as director of the company’s bioproduction sites in Belgium. Read More

Quintiles has named Tom Pike as CEO. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here